2026-04-14T05:00:23Zhttps://recercat.cat/oai/request

oai:recercat.cat:10459.1/4688232025-10-20T18:03:44Zcom_2072_3622col_2072_479130

Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma Garcia-Guiñón, Antoni Charry, Paola Andrea Jimenez, María Sarra, Josep Delgado, Izarbe Segura de la Torre, Laura Santaliestra, Marta Garcia-Pintos, Marta Gonzalez, Yolanda Senin, Alicia Motlló, Cristina Abella, Eugènia Cabezudo, Elena Granell, Miquel Sancho, Esther Herranz, María José Seres, Yasmina Gironella, Mercedes Soler, Juan Alfons Marti-Tutusaus, Josep Maria Ben Azaiz, Ran Fernandez de Larrea, Carlos Carfilzomib, lenalidomide and dexamethasone Real-world Relapsed/refractory multiple myeloma Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there is limited real-world evidence. Here we evaluated the efficacy and safety of KRd in patients with RRMM treated following the standard clinical practice of the hospitals in the Catalan region. This was a retrospective, observational study. The objective response rate (ORR) according to IMWG criteria was the primary endpoint. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). The study planned to include at least 100-150 patients. In total 194 patients were included. Median age was 64 years (range: 40-88) and 56% were male. All patients had received bortezomib. Additionally, 89 patients (46%) had received thalidomide and 29 (15%) lenalidomide. The ORR was 73% (95% CI: 66-79), with 72 patients (37%) having ≥ CR. The ORR was influenced by ISS score, number of previous treatments and exposure to lenalidomide. The median PFS was 26 months and 2-years OS rate 70%. The ISS stage and LDH levels were independent prognostic factors of survival. In conclusion, the KRd scheme led to a good effectiveness comparable safety profile to the phase III clinical trial in patients with RRMM. 2025-10-20T18:03:43Z 2025-10-20T18:03:43Z 2025-10-20T18:03:43Z 2025 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/10459.1/468823 Reproducció del document publicat a: https://doi.org/10.1007/s00277-025-06240-1 Annals of Hematology, 2025, vol. 104, núm. 2 cc-by-nc (c) The Authors, 2025 Attribution-NonCommercial 4.0 International info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc/4.0/ Springer